Q’Apel Medical, Inc. Awarded U.S. Patent for Its Highly Innovative SelectFlex™ Technology

Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, is pleased to announce today that the United States Patent & Trademark Office has granted the company U.S. Patent No. 11,123,522 covering important features of its differentiated dual-mode catheter designs.

The SelectFlex™ variable stiffness technology provides unparalleled tracking and support in neurovascular access cases. Comprised of two operational modes, tracking mode and support mode allows physicians to switch between modes on-demand in a clinical case. By injecting 0.2cc of saline, and the technology goes into track mode, becoming soft and flexible for tracking into distal neurovasculature. By applying vacuum, the technology transitions into support mode, maintaining its shape and resists bending.

“SelectFlex™ technology is an important innovation for Q’Apel Medical because it allows us to make catheters that have a mix of trackability and support that is unparalleled in the industry. We can transition from very soft and flexible to highly supportive device on the fly during the case, and it is easily controlled by the user. We look forward to continue differentiating our products through the application of SelectFlex™ technology,” said Jeff Krolik, CTO.

“Our ability to identify unmet clinical needs and build cutting-edge solutions in a timely manner is what differentiates us from our contemporaries. The SelectFlex™ technology plays a huge role in our success and is foundational in our product pipeline,” said King Nelson, CEO.

Q’Apel Medical has other pending patent applications and plans to acquire CE Certification and expand into Europe later this year. Q’Apel Medical products are currently being utilized in over 200 hospital systems nationwide.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version